Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin 10 mg vs placebo in elderly Japanese patients with type 2 diabetes mellitus
jRCT1080225321Phase 4Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Empagliflozin 10 mg with Placebo (2 arms). Primary endpoint: Change from baseline in HbA1c at 52 weeks. Started Aug 2020; status: completed.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT1080225321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080225321.